Cony D'Cruz, Superluminal Medicines CEO & co-founder

For­mer Schrödinger ex­ec launch­es RA Cap­i­tal-backed start­up for AI drug dis­cov­ery

Su­per­lu­mi­nal Med­i­cines, a start­up claim­ing that it can use ar­ti­fi­cial in­tel­li­gence to shrink the de­vel­op­ment of pre­clin­i­cal drug can­di­dates from years to a mat­ter of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.